GleamWall
中文EN

MNPR Monopar Therapeutics

Pharmaceutical Preparations · Nasdaq · SEC CIK 1645469 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-6.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-15.3%
ROA-15.0%
ROIC (approx.)-45.6%
Asset turnover—

Leverage & solvency

Liabilities / assets2.4%
Debt / equity0.00x
Current ratio43.55x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$9.90M$13.01M
SG&A expense$6.80M$3.16M
Operating income-$16.70M-$16.16M
Pretax income-$13.72M-$15.59M
Income tax$800$800
Net income-$13.72M-$15.59M
EPS (basic)-1.85-4.11
EPS (diluted)——
Balance sheet
Cash & equivalents$61.83M$45.82M
Short-term investments$60.88M$45.53M
Current assets$140.46M$60.29M
Total assets$140.72M$60.29M
Current liabilities$2.74M$5.25M
Total liabilities$2.89M$5.25M
Shareholders' equity$137.83M$55.04M
Shares outstanding6.69M6.10M
Cash flow statement
Operating cash flow-$12.20M-$6.40M
Investing cash flow-$63.45M-$14.34M
Financing cash flow$91.57M$59.29M
Stock-based compensation$4.84M$1.14M
Share buybacks$35.00M$0

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.